1-[[4-(1,4,8,11-Tetrazacyclotetradec-1-ylmethyl)-1-naphthyl]methyl]-1,4,8,11-tetrazacyclotetradecane

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-[[4-(1,4,8,11-Tetrazacyclotetradec-1-ylmethyl)-1-naphthyl]methyl]-1,4,8,11-tetrazacyclotetradecane
• 英文别名: 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)naphthalen-1-yl]methyl]-1,4,8,11-tetrazacyclotetradecane
• 化学式: C₃₂H₅₆N₈
• 分子量: 552.8
• InChiKey: MSNPWEIMBZUZLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  40
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  78.7
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• Linked cyclic polyamines with activity against hiv.
  申请人：AnorMED Inc.

  公开号：EP1223166A1

  公开（公告）日：2002-07-17

  There is disclosed a pharmaceutical composition comprising as active ingredient a linked cyclic compound of general formula I,         Z - R - A - R' - Y     (I) in which Z and Y are independently cyclic polyamine moieties having from 9 to 32 ring members and from 3 to 8 amine nitrogens in the ring spaced by 2 or more carbon atoms from each other,    A is an aromatic or heteroaromatic moiety,    R and R' are each a substituted or unsubstituted alkylene chain or heteroatom containing chain. or an acid addition salt or metal complex thereof, in admixture or association with a pharmaceutically acceptable diluent or carrier.

  揭示了一种药物组合物，其包含一种作为活性成分的一般式I的环链化合物，其中Z和Y分别是具有9至32个环成员和3至8个胺氮的环状多胺基团，这些胺氮在环中相距至少2个或更多个碳原子，A是芳香或杂芳基团，R和R'分别是取代或未取代的烷基链或含有杂原子的链，或其酸盐或金属络合物，与药用可接受的稀释剂或载体混合或结合。
• Chemokine combinations to mobilize progenitor/stem cells
  申请人：Bridger J. Gary

  公开号：US20060035829A1

  公开（公告）日：2006-02-16

  Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 in combination with the CXCR2 chemokine GROβ, including its modified forms, are disclosed.

  使用与趋化因子受体CXCR4结合的化合物与CXCR2趋化因子GROβ及其改良形式结合，揭示了提高动物主体中祖细胞和干细胞数量的方法。
• Methods to mobilize progenitor/stem cells
  申请人：——

  公开号：US20030130250A1

  公开（公告）日：2003-07-10

  Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z′  (1) or pharmaceutically acceptable salt thereof wherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms, said nitrogen atoms separated from each other by at least 2 carbon atoms, and wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system; or Z is of the formula 1 wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1-20 atoms, Z′ may be embodied in a form as defined by Z above, or alternatively may be of the formula —N(R)—(CR 2 ) n —X wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan; “linker” represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.

  公开了一种使用与趋化因子受体CXCR4结合的化合物来提高动物主体和干细胞数量的方法。这些化合物的首选实施例为以下公式所示：Z-连接物-Z′（1）或其药用盐，其中Z是含有9-32个环成员的环状多胺，其中3-8个是氮原子，所述氮原子彼此之间至少相隔2个碳原子，且所述杂环除了氮原子外还可以包含额外的杂原子和/或与额外的环系统融合；或者Z为以下公式1所示：其中A包括至少一个N的单环或双环融合环系统，B为H或1-20个原子的有机基团，Z'可以采用如上所定义的Z的形式，或者也可以是以下公式的形式：-N（R）-（CR2）n-X其中每个R独立地为H或直链、支链或环烷基（1-6C），n为1或2，X为芳香环，包括杂芳环，或者是硫醇；“连接物”代表键，烷基（1-6C）或可能包含芳基、融合芳基、含在烷基链中的氧原子，或者可能含有酮基团、氮原子或硫原子。
• Dosing regimens for the mobilization of hematopoietic stem cells
  申请人：Magenta Therapeutics Inc.

  公开号：US10058573B1

  公开（公告）日：2018-08-28

  Described herein are compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a subject, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the composition and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others.

  本文描述的组合物和方法可用于动员受试者体内的造血干细胞和祖细胞群，以及确定动员细胞样本是否适合释放用于体外扩增和/或治疗用途。根据本文所述的组合物和方法，动员的造血干细胞和祖细胞可从供体中提取并施用给患者，用于治疗各种疾病，包括造血疾病、代谢性疾病、癌症和自身免疫性疾病等。
• Mobilizing agents and uses therefor
  申请人：The University of Queensland

  公开号：US10933049B2

  公开（公告）日：2021-03-02

  The present invention discloses the use of a complement 3a receptor (C3aR) antagonist and a mobilizer of hematopoietic stem cells and/or progenitor cells in methods and compositions for stimulating or enhancing the development, mobilization, proliferation and/or differentiation of a neutrophil-containing leukocyte population that inhibits growth and/or spread of a tumor and for treating or preventing a hyperproliferative cell disorder.

  本发明公开了补体3a受体（C3aR）拮抗剂和造血干细胞和/或祖细胞动员剂在刺激或增强含中性粒细胞的白细胞群的发育、动员、增殖和/或分化的方法和组合物中的应用，该方法和组合物能抑制肿瘤的生长和/或扩散，并能治疗或预防细胞过度增殖症。